Selecting a Treatment Regimen
Table 11. Hypoglycemic Agentsa Generic (Brand)
Dose
TZDs (continued) Use restricted. )
Rosiglitazone (Avandia®
Rosiglitazone + metformin (Avandamet®
)
Rosiglitazone + glimepiride (Avandaryl®
)
Initial: 4 mg daily or 2 mg bid
Initial: 2 mg/500 mg bid
Max: 8 mg daily or 4 mg bid
Max: 4 mg/1000 mg bid (continued)
Initial: 4 mg/1 mg or 4 mg/2 mg daily
Max: 8 mg rosiglitazone and 4 mg glimepiride daily
a • Should not be used in patients with T1DM or for the treatment of diabetic ketoacidosis. • Dose adjustments should be made based on periodic HbA1c tests. • Titration to response within the dosing range will determine maintenance dose. • See specific product labeling for complete prescribing information including precautions and warnings.
Table 12. Pharmacokinetics of Human Insulin and Insulin Analogs
Insulin Generic (Brand)
Rapid-acting Aspart injection (NovoLog® Lispro injection (Humalog® Glulisine injection (Apidra®
Short-acting Regular
Intermediate, basal NPH
Long-acting, basal Glargine injection (Lantus® Detemir injection (Levemir®
) ) Premixed
75% lispro protamine suspension 25% lispro injection (Humalog®
Mix 75/25™ Mix 70/30) )
70% aspart protamine suspension 30% aspart injection (NovoLog®
70% NPH/30% Regular 24 5-15 min a The biphasic insulins have a single broad skewed (asymmetric) peak. Broada 30-60 min Broada 10-16 h 10-16 h 5-15 min Broada 10-16 h ) ) ) Onset
5-15 min 5-15 min 5-15 min
Peak
Effective Duration
30-90 min < 5 h 30-90 min < 5 h 30-90 min < 5-8 h
30-60 min 2-3 h 2-4 h
2-4 h 3-8 h
4-10 h
"Flat" "Flat"
5-8 h 10-16 h 20-24 h 5.7-23.2 h
